Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of thre...

Full description

Bibliographic Details
Main Authors:	Tan Chongqing, Li Sini, Zeng Xiaohui, Peng Liubao, Peng Ye, Qin Shuxia, Wang Liting, Wu Meiyu, Wan Xiaomin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Pharmacology
Subjects:	pembrolizumab colorectal neoplasms immunotherapy cost-effectiveness microsatellite-instability-high/mismatch repair-deficient
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.802942/full

Similar Items

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022-05-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022-02-01)

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
by: Liting Wang, et al.
Published: (2023-01-01)

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
by: Liting wang, et al.
Published: (2023-01-01)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
by: Meiyu Wu, et al.
Published: (2022-04-01)

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study
by: Shuxia Qin, et al.
Published: (2022-08-01)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
by: Ye Peng, et al.
Published: (2021-11-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
by: Qiao Liu, et al.
Published: (2021-01-01)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
by: Motohiro Fujiwara, et al.
Published: (2020-03-01)

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
by: Yuki Ikeda, et al.
Published: (2021-04-01)

Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study
by: Meiyu Wu, et al.
Published: (2023-07-01)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.
by: Sini Li, et al.
Published: (2020-01-01)

Evaluation of mismatch-repair and microsatellite-instability status in a Chinese colorectal cancer Cohort
by: Peng Zhang, et al.
Published: (2024-02-01)

Mismatch Repair Deficiency and Microsatellite Instability
by: Sandra Schöniger, et al.
Published: (2022-08-01)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
by: Masaya Senda, et al.
Published: (2023-11-01)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022-04-01)

Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series
by: David D Stenehjem, et al.
Published: (2018-07-01)

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability
by: Madhura Deshpande, et al.
Published: (2020-11-01)

Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
by: Chongqing Tan, et al.
Published: (2013-01-01)

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
by: Giuseppe Lombardi, et al.
Published: (2020-08-01)

Microsatellite instability and mismatch repair protein deficiency: equal predictive markers?
by: Maja L. Nádorvári, et al.
Published: (2024-04-01)

Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
by: Wei-Jian Mei, et al.
Published: (2022-12-01)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
by: Takumi Kageyama, et al.
Published: (2022-11-01)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
by: Pengfei Zhao, et al.
Published: (2019-05-01)

Long-term disease-free survival with chemotherapy and pembrolizumab in a patient with unmeasurable, advanced stage dedifferentiated endometrial carcinoma
by: Joy M. Davis, et al.
Published: (2024-06-01)

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
by: Tian Zeng, et al.
Published: (2021-11-01)

Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
by: Xin-yu Ren, et al.
Published: (2021-03-01)

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
by: Birgit S. Geurts, et al.
Published: (2023-03-01)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021-08-01)

Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers
by: Chien-Hsiang Kao, et al.
Published: (2024-04-01)

Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective
by: Tomas Buchler
Published: (2022-04-01)

Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series
by: Maja L. Nádorvári, et al.
Published: (2024-02-01)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
by: Romain Cohen, et al.
Published: (2021-03-01)

Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
by: Yannan J. Wang, et al.
Published: (2021-02-01)

A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
by: Siying Wang, et al.
Published: (2013-01-01)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021-11-01)

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report
by: Mohammad O. Atiq, et al.
Published: (2023-03-01)

Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
by: Maia L. Valls, et al.
Published: (2022-06-01)